Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5387_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •Foreword
- •Preface
- •About the Editors
- •Contributors
- •References
- •2.3.4 Barriers to Automation Adoption
- •2.4 Core Ingredients for Successful Digital Transformation
- •2.1 Introduction
- •2.3.1 Operational Challenges
- •2.3.2 Cultural Challenges
- •2.4.2 Cloud Computing
- •2.5 Case Studies of Successful Digital Transformation
- •2.6 Conclusion
- •References
- •3. Computational Protein Design Strategies for Optimization of Antigen Generation to Drive Antibody Discovery
- •3.1 Introduction
- •3.3 Antigen Generation Strategies
- •3.4 Computational Methods
- •3.4.2 Computational Protein Structure Prediction
- •References
- •4. Bioinformatic Analyses of Antibody Repertoires and Their Roles in Modern Antibody Drug Discovery
- •4.1 Introduction
- •4.6 Summary and Future Directions
- •Acknowledgments
- •References
- •5.1 Introduction
- •5.2 Databases
- •5.2.1 Databases in Machine Learning Approaches
- •5.2.2 Database Types
- •5.3 Applications of Machine Learning in Antibody Discovery and Development
- •5.3.1 Structure Prediction with Deep Learning
- •5.3.3 Developability
- •5.4 Antibody Generation and Design by Language Models
- •5.4.1 Antibody Representations
- •5.4.2 Representation Learning
- •5.4.3 Language Models
- •References
- •6.1 Introduction
- •6.2 Antibody Generation through Deep Generative Models
- •6.3.1 Sampling and Scoring
- •6.5 Conclusions and Perspectives
- •Acknowledgments
- •References
- •7.1 Introduction
- •7.2.3 Computational Approaches to Predict Antibody–Antigen Interaction
- •7.3 Conclusion
- •Competing Interests
- •Acknowledgments
- •References
- •8.2 Common Types of Molecular Simulations for Biomolecules
- •8.2.1 Molecular Dynamics (MD) Simulations
- •8.2.2 Monte Carlo (MC) Simulations
- •8.2.3 Challenges of Molecular Simulations
- •8.3.1 Periodic Boundary Conditions
- •8.4 Uses of Molecular Simulation in Antibody Drug Development
- •8.5 Conclusion
- •References
- •9. Considerations of Developability During the Early Stages of Antibody Drug Discovery and Design
- •9.1 Introduction
- •9.2 Historical Perspective
- •9.3 Clinical Antibody Data Set
- •9.5 Control Antibodies
- •9.7 Assessment of Chemical Liabilities
- •9.8 Conclusions and Future Perspectives
- •Acknowledgments
- •References
- •Abbreviations
- •10.1 Introduction
- •10.4.1 Conclusions and Outlook
- •Acknowledgments
- •References
- •11.8 Conclusions and Future Directions
- •References
- •12.1 Introduction to PK/PD and QSP Modeling
- •12.1.1 PK/PD Modeling
- •12.1.2 QSP Modeling
- •12.2.1 Monoclonal Antibodies (mAbs)
- •12.2.3 Cell Therapies
- •12.2.4 Gene Therapies
- •12.2.5 Vaccines
- •12.2.6 mRNA/siRNA/Oligonucleotide Therapeutics
- •12.4 Case Studies
- •12.5 Conclusions and Future Perspectives
- •References
- •13.1 Introduction
- •13.2 AI/ML: A Game Changer for Antibody Design
- •13.3 Multispecific Antibody Design
- •13.4 Adapting AI to the Design of Multispecific Antibodies
- •13.4.1 Structure Prediction and Modeling
- •13.4.2 Developability Prediction and Optimization
- •13.4.4 In Silico Modeling and Simulation
- •13.5 The Future: Beyond Optimization
- •13.5.1 Market Trends and Commercialization
- •13.5.2 Logic Gates, Biosensors, and De Novo Design
- •13.5.3 Challenges and Opportunities
- •13.6 Conclusion
- •Acknowledgments
- •References
- •Index

8 • Antibody Structural Dynamics 211
B
22
B
22
B
22
B
22
B
22
B
22
At these high concentrations, protein‑protein interactions between mAbs drive self‑
association and determine viscosity.
60,61
As a result of differences in their self‑interaction
proles, some mAbs may have poor solubility and not reach the required concentration
for effective delivery; some may demonstrate prohibitively high viscosity for comfortable
injection; yet others may aggregate irreversibly.
In the development pipeline, experimental methods are used to assess a mAb’s
physical and chemical properties and response to environmental conditions like salt
concentration
55,62,63
to judge its “developability”. These methods are, however, time con‑
suming and consumptive of mAb material. In response, computational ways to both
predict and understand what mAb structures give rise to the properties of concentrated
mAb solutions have been developed in the academic literature. Some of these meth‑
ods leverage information from available experimental structures of known therapeutic
antibodies to dene developability guidelines.64 These methods do not, however, pro‑
vide information about what structures these antibodies populate that give rise to their
behavior in solution. Simulation methods have also been designed to address this short‑
coming.
55,59,65
Some of these methods take a small amount of experimental data as input
and extrapolate to diverse solution conditions. Yet other methods are designed to work
in tandem with experimental methods to answer the inverse question of what structures
give rise to an observed experimental signal. As their goal is predicting protein‑protein
interaction‑based parameters, these methods typically consider multiple copies of the
mAb of interest at a CG resolution to control computational costs. In the following three
case studies, we describe important lessons learned from CG models of concentrated
antibody solutions.
Case Study 8.1: Predicting the response
ofmAb solutions to salt and pH
The propensity of mAbs to self‑interact in low‑concentration regimes can be assessed
experimentally through the second osmotic virial coefcient,
.55 Its values are a
commonly used proxy for protein‑protein interactions in a dilute solution, with positive
values indicating repulsive interactions and negative values indicating attractive interac‑
tions. In situations in which a mAb displays strong protein‑protein interactions, such as
at higher concentrations, higher‑order virial coefcients that report on the formation of
higher‑order oligomers may also be computed. Shahfar and co‑workers55 compared the
ability of four different CG models (Figure8.2a) to predict
as a function of the total
ionic strength (TIS) for mAb1, mAbB, mAb2, and mAbC.
Diverse qualitative behavior in experimental
versus TIS curves is observed;
mAb1, mAbB, and mAb2 can serve as exemplars of the different behaviors displayed
by mAb solutions as TIS changes (Figure8.2b). mAb1 at pH 5 displays large positive
values at low values of TIS in the solution, with a monotonic decrease observed as
TIS increases (Figure8.2b, blue). mAbB at pH 5 displays values near zero at low TIS,
negative values at intermediate TIS, and then increases monotonically with increasing
TIS to a plateau near zero (Figure8.2b, green). Finally, mAb2 at pH 6.5 displays large
magnitude negative values of
TIS increases (Figure8.2b, yellow). In each of these examples,
at low TIS that increase monotonically toward zero as
versus TIS curves

212 Biopharmaceutical Informatics
B
22
B
22,ST
y
GB/2
22 22,ST
−
FIGURE8.2 (a) All-atom and CG models from Shahfar etal. (2021). (b) Experimental second virial coefcient versus TIS curves for mAb1 at pH 5 (blue), mAbB at pH 5 (green), and
mAb2 at pH 6.5 (yellow). (c) Experimental (black symbols) and CG model predicted second
virial coefcient versus TIS curves for the HEXA (blue), DODECA (green), 1bC/D (yellow),
and 1bAA (purple) for mAb1 at pH 5. (d) Same as (c) but for mAbB. (e) Same as (c) but
for mAb2 at pH 6.5. (f) Same as (c) but for mAbC.
is the second virial coefcient and
is the second virial coefcient under the assumption of steric-only interactions. The
-axis in panel F is denoted
because the large values suggest the formation
of higher-order oligomers. (g) DODECA models used by Wang etal. for mAb1 (left) and
mAb2 (right). Red and blue beads indicate negative and positive net charges, respectively.
Panels A-F reprinted with permission from Shahfar, H.; Forder, J. K.; Roberts, C. J. J. Phys.
Chem. B 2021, 125 (14), 3574–3588. Copyright 2023 American Chemical Society. Panel G
reprinted with permission from Wang, G. etal. J. Phys. Chem. B 2018, 122 (11), 2867–2880.
Copyright 2023 American Chemical Society.
can be understood in terms of the interactions that predominate in each mAb solution as
TIS changes. For mAb1, the behavior is as predicted for a colloid‑like system in which
high net surface charge leads to repulsive interactions at low ionic strength that become
screened as TIS increases, leading to a plateau near zero at high TIS. mAbB contains
both positive and negative charges that can interact attractively, leading to attractive

8 • Antibody Structural Dynamics 213
B
22
B
22
B
22
B
22
B
22
interactions at intermediate TIS when screening is at a favorable level. In the case of
mAb2, the results are consistent with a mAb with a low net charge but with charged
patches that can strongly attract one another at low TIS and become screened as TIS
increases.55 These experimental curves indicate that a CG model must be able to account
for various behaviors in order to accurately predict the different behaviors of mAbs.
To predict the
versus TIS curves for mAb1, mAbB, mAb2, and mAbC, Shahfar
and co‑workers constructed CG models with (i) one bead per amino acid (1bAA),
(ii) 12 beads total with one each per domain in the mAb and the net charge of its
constituent amino acids applied to each site (DODECA), (iii) 12 beads total with
charged amino acids represented as charged patches on the beads (1bC/D), and (iv)
six beads total with two for each Fab and the Fc and the net charge applied to each
bead (HEXA). Simulations were run using the Mayer sampling method66 with the
overlap sampling algorithm to compute values of
and higher‑order virial coef‑
cients; this amounts to a specialized MC sampler that biases the simulations to
preferentially explore states that contribute most to the nal value of a given virial
coefcient. Within each of these CG models, solvent is considered implicitly, and
similar functions are used to represent their short‑range non‑electrostatic and elec‑
trostatic interactions as functions of SR and
strength (well‑depth) of non‑electrostatic interactions between sites and
, respectively. SR sets the maximum
is an
adjustment factor that scales the theoretical charges of CG sites. Values of SR and
were selected based on test simulations for each CG model until pairs of parameters
that minimize the average relative deviation from the experimental
versus TIS
curves were determined.
For mAb1, which displays standard colloid‑like behavior, each of the four CG models
provides a reasonably good t at pH 5, with the 1bAA model displaying the small‑
est deviation from the experiment (Figure 8.2c). In the case of mAbB at pH 5, the
DODECA and HEXA models fail to predict the correct shape of
at low TIS, while
the 1bC/D and 1bAA models both provide strong predictions of the experimental data
(Figure8.2d). With mAb2 at pH 6.5, each of the four models again makes reasonable
predictions, while for mAbC at pH 5, the HEXA and DODECA models completely fail
to capture the shape of the experimental curve (Figure8.2e and f). These results indi‑
cate that a bespoke modeling process for understanding the inuence of salt is required,
with some mAbs proving to be less tractable than others and requiring more expensive,
higher‑resolution CG models. Shahfar etal. provide a table of CG model parameters for
their different mAbs that can help choose reasonable parameters for simulations even in
the absence of experimental data (see Ref. 55 Table1).
This MC investigation of the inuence of pH on low‑concentration mAb solutions
highlights the challenges and future directions for such predictive models. Strong ts
to experimental data tend to be obtained when at least 12 CG interaction sites are con‑
sidered with amino‑acid‑specic charge representations rather than domain‑level net
charge electrostatics (i.e., 1bC/D). Models using one CG interaction site per amino acid
also provide strong predictions, though at a higher computational cost. Even in some
more difcult cases, CG simulations can reproduce the ne structure of experimental
curves.

214 Biopharmaceutical Informatics
Aα= HVI*
H
V
Case Study 8.2: Predictive models for the properties
of high‑concentration mAb solutions
Signicant interest in recent years has been focused on the development of CG models
coupled with either MD or MC sampling methods to predict mAb solution viscosity. Wang
and co‑workers67 ran Brownian Dynamics simulations using 12‑bead CG representations
of two mAbs, mAb1 and mAb2, that have 92% sequence similarity. Despite their highly
similar sequences, these mAbs have disparate rheological behavior, with the viscosity of
mAb1 varying much more strongly in response to changes in its concentration, pH, and
the ionic strength of the solution.61 The initial simulations of Wang and co‑workers were in
poor agreement with experimental relative viscosity measurements. Inthese initial simu‑
lations, CG beads within a single mAb molecule interact through bond, angle, dihedral,
and Urey‑Bradley terms (additional forceeld terms to account for angle bending), and
each CG bead is assigned a charge equal to the net charge of the particles it represents
(Figure8.2g). The spring constants and equilibrium values for the CG bead interactions
were computed from all‑atom MD simulations of a single mAb molecule.
68
Wang and co‑workers noted that in scattering experiments, mAb1 has been found
to form reversible dimers and higher‑order oligomers.
60,69
These dynamically forming
and breaking groups of self‑associated mAbs are referred to as clusters. Upon adding
additional constraints to their CG simulations that cause groups of self‑associated CG
mAbs to move together rigidly, simulation results for both mAb1 and mAb2 signi‑
cantly improve. In these new results, mAb2’s viscosity as a function of concentration is
predicted well, while the prediction of mAb1’s viscosity is improved but still inaccurate
at high concentrations. These simulation results indicate the importance of considering
soluble clusters of mAbs in simulations for the prediction of mAb viscosity.
In a follow‑up to the work of Wang etal., Lai and co‑workers attempted to improve
this 12‑bead CG model’s ability to capture changes in viscosity with mAb concentra‑
tion by making a key modication to interactions within the model.70 Rather than using
a single constant interaction energy between all CG beads regardless of the part of the
mAb they represent, they incorporate separate Fv and Fc interaction terms. Interaction
strengths between Fv regions are determined using the high‑viscosity index (HVI), a
parameter relative to viscosity developed using a machine‑learning approach,71 and then
scaled by a tting parameter
specic term
. Interactions between mAbs depend, then, on an Fv‑Fv
, an Fc‑Fc specic term set to a constant for all Fcs, and
electrostatic forces dependent on the net charge of the CG interaction site. Equilibrium
values and force constants for CG interactions were determined from all‑atom simula‑
tions of each mAb, as in the work of Wang etal. Values for
and the strength of Fc
interactions were determined using a grid search to nd the pair of parameters that
best predicts the viscosity of a 150‑mg/mL mAb solution over all 20 mAbs studied.
This simple tting procedure generates models that provide accurate relative viscosity
predictions for [mAb] = {50, 100, 125, 150} mg/mL for a set of 20mAbs. In comparison
to the original model of Wang etal., the root‑mean‑square deviation improves from 1
to 0.68 and the correlation coefcient improves from 0.63 to 0.87. Despite better per‑
formance on the data set overall, the original model of Wang and co‑workers performs
better than that of Lai and co‑workers on mAb2.

8 • Antibody Structural Dynamics 215
A
H
V
= 1
Pq
()
q
π
λ
θ
4
2
Lai and co‑workers also, for the rst time, explored the inuence of the size of the
simulated system on the calculated relative viscosity. In principle, an innite number of
simulation boxes with different volumes can be designed and then lled with an appro‑
priate number of mAb representations to reach a desired concentration. All publications
investigating mAb solution viscosity prior to this simulated only a single box size. Lai
and co‑workers, however, demonstrated that changing the size of the simulation box
inuences the calculated relative viscosity. With
, the simulations predict a 3‑fold
larger viscosity when run with a box containing N = 4,096monomers versus a smaller
box with N = 512monomers. This result breaks one of our basic intuitions for how a
chemical system should behave: if we have 10 mL of 1.0 M NaCl and split the solution
into two 5‑mL aliquots, we expect each of them to have identical intensive properties
like viscosity to the initial solution before it was split. In the case at hand, this illogical
result is a simulation artifact that arises due to the dependence of viscosity on the size of
self‑associated clusters formed in the nite simulation box. The calculation of the vis‑
cosity can only consider the clusters formed within the simulation box—for large cluster
sizes and small periodic boxes, however, the effective cluster extends through the peri‑
odic boundary conditions. This leads to computed viscosities that depend on the size of
the simulation box with mAb concentration held constant. When interactions between
mAbs are weak and clusters tend to be small, this dependence disappears.
These studies of high‑concentration mAb solutions highlight that Fv‑specic interac‑
tions are crucial for predicting protein‑protein interactions in high‑concentration mAb
solutions. The dependence of the cluster‑size distribution on the simulation box dimen‑
sions is a particularly troubling simulation challenge.
Case Study 8.3: Tandem experimental and
simulation studies of mAb solutions
While the previous two case studies have focused on using CG methods to predict
the solution properties of mAbs with minimal reliance on experimental data in their
parameterization procedures, other CG models have been designed to work exclusively
in tandem with experiments.
59,62
In such studies, experimental small‑angle X‑ray scat‑
tering (SAXS) or small‑angle neutron scattering (SANS) data are used as a target during
CG model optimization and parameters chosen that minimize the deviation between
simulated and experimental scattering data.
59,62
The scattering data may also be rened
into an all‑atom model, from which a CG representation is then constructed.59 While
these methods are not, strictly speaking, predictive models for viscosity, the best‑t
simulations can provide a wealth of information about cluster‑size distributions and help
understand the dynamic oligomeric states populated by mAbs in solution.
In the work of Dear and co‑workers,62 SAXS experiments at [mAb] = 5 mg/mL
were used to assign a mAb shape by tting to
=
a function of
sin
where λ is the wavelength of the incident X‑ray and
, the normalized form factor, as

216 Biopharmaceutical Informatics
Pq
()
is the scattering angle. The scattering pattern represented by the form factor is
related to the size and shape of the protein in the solution.72 In general, low concen‑
trations of 1–10 mg/mL are used to provide a compromise between the increase in
signal‑to‑noise ratio and the decrease in interparticle distances that both accompany
increased solution concentration. While the former is always favorable, the latter
can inuence the scattering pattern. In practice, proles collected at different con‑
centrations may be merged into a single representative curve. Solutions of mAb2 at
[NaCl] = 0, 50, 250 mM and with [Arg] = 250 mM and mAb4 with either 250‑mM
NaCl or Arg were all assayed with SAXS, and the resulting
12‑bead CG models with various interaction proles. While each of the CG mod‑
els for a particular mAb and solution condition have identical bead sizes and loca‑
tions, they differ in terms of how many beads experience attractive interactions and
where these attractive beads are placed within the CG model. MD simulations were
run with 6,000 identical mAb CG representations in a periodic box with a constant
number of particles, system volume, and system temperature for each mAb and CG
model. They nd that models with only three attractive beads per mAb are frequently
detected bound to more than three neighbors. This result appears to invalidate theo‑
retical models that only allow one interaction partner per binding site.
low‑up paper, Chowdhury and co‑workers investigated the inuence of short‑range,
non‑electrostatic attractive and electrostatic repulsive interactions. Using a similar
tting and simulation procedure to Dear etal., Chowdhury and coworkers59manipu‑
lated the parameters within the CG model to best t the experimental structure factor
curves under various conditions for mAb2. These simulations found that including
uniform VDW interactions between all model beads allows predictions of structure
factor curves to become more accurate.
These simulation results highlight the ability of CG simulations to aid in understand‑
ing the difcult inverse question that accompanies spectroscopic assays of biomolecules:
what ensemble of structures gives rise to the observed signal? In this case, exploring
various CG models and rationalizing which models provide the best predictions for
which system provides a wealth of additional information beyond the experiment alone.
As computational power increases and model accuracy continues to improve, the use of
CG simulations to understand the ne structure of experimental scattering curves may
become more commonplace.
curves used to build
73,74
In a fol‑
8.4.2 Predicting and Understanding Binding
Mechanisms, Energetics, and Aggregation
The following three case studies highlight the use of all‑atom simulations to understand
and predict the mechanisms and energetics of mAbs interacting with their targets as well
as the aggregation propensity of mAbs. While all‑atom simulations have become more
common in the academic literature, their high computational cost limits their applica‑
tion across the development pipeline. As enhanced sampling techniques and simulation

8 • Antibody Structural Dynamics 217
speeds continue to improve, however, we expect to see an ever‑increasing reliance on
the predictions of all‑atom MD.
Case Study 8.4: Predicting the binding mechanism
and oligomeric preference of solanezumab
Bekker etal. (2020) ran multicanonical MD simulations, in which structures from tra‑
jectories run at different temperatures may be reweighted to provide better sampling
at a specic temperature of interest, of solanezumab binding to the monomeric form
of its target peptide amyloid‑β (Aβ, Figure8.3a).75 In these simulations, the Fv region
of solanezumab was held partially restrained, and the center of mass of Aβ was then
allowed to explore conformations within a cylinder positioned normal to the solane‑
zumab binding site. This combination of multicanonical MD with positional restraints
increases the speed of the conformational search relative to single‑temperature simu‑
lations and reduces the number of accessible conformations for the solanezumab/Aβ
system, enhancing sampling.
A free‑energy landscape projected onto the two principal components (PC1 and PC2)
of this simulation suggested that the solanezumab Fv explores a diverse conformational
landscape at 300 K around the experimental structure (Figure8.3b, experimental struc‑
ture indicated by a white X). Bekker etal. 2020 then selected a set of ten structures from
the free‑energy landscape representing steps along the binding reaction and performed
path‑sampling simulations to characterize the binding mechanism. These path‑sam‑
pling simulations revealed the mechanism of interaction between solanezumab and
Aβ. As the peptide approaches the antibody, transient non‑specic interactions begin to
form. Once it reaches 8–10 Å from the binding pocket center of mass, the hydrophobic
core of the pocket begins to interact via CDRH1 and CDRL1 (observed as a metastable
plateau in the potential of mean force, Figure8.3c). Many individual native contacts are
made as the peptide nears the core, with non‑specic interactions gradually becoming
stabilized by salt bridges. Bekker etal. 2020 conclude by simulating Aβ in isolation,
revealing (consistent with previous work76) that Aβ explores disordered structures in the
unbound state.
Comparing their results to the three typical binding models of (i) lock and key, (ii)
population shift, and (iii) induced t, Bekker and co‑workers determined that their
results are most consistent with what they term a “mutual population shift”. Each mol‑
ecule undergoes random structural perturbations until it is in a native‑like state, which
allows it to rapidly bind if its partner is nearby and also in a native‑like state. In other
words, if a molecule of both the mAb and the peptide are both in native‑like states in
close proximity, they form a bound complex. Their structure and mechanism of inter‑
action also provide an explanation for the substrate selection of solanezumab: only the
monomeric form of Aβ is able to t deep enough within the solanezumab binding pocket
to induce a conformational shift away from the random states it populates in solution.
These all‑atom MD simulations highlight the strengths of this technique, providing a
detailed binding mechanism along the chosen order parameter.

218 Biopharmaceutical Informatics
(Continued)

8 • Antibody Structural Dynamics 219
FIGURE8.3 (Continued) (a) Simulation setup of Bekker etal. 2020. (b) Free-energy landscape from all-atom simulations of solanezumab (labeled L and H for variable light and
variable heavy) and Aβ peptide at 300 K. (c) Potential of mean force over the order param-
eter λ′, the distance between the peptide and binding pocket. (d) Fractional contributions to
total receptor free energy from the peptide, α1, and α2 helices. (e) Fractional contributions
of CDR loops to total ligand-free energy. (f) The temperature at which a set of ten Fvs pass
below solubility thresholds during temperature-ramp all-atom MD. (g) Percent change in
aggregation for 13mAb solutions after 3 months of storage at 40°C. Panels a–c: Reprinted
with permission from Bekker, G. J. etal. Sci. Rep. 2020, 10 (1), 1–9 (Creative Commons
Attribution 4.0, https://creativecommons.org/licenses/by/4.0/). Panels f and g: Reprinted
with permission from Berner, C. et al. Mol. Pharm. 2021, 18 (6), 2242–2253. Copyright
2023 American Chemical Society.
Case Study 8.5: Predicting and understanding the energetics
of interactions between antibodies and their targets
All‑atom simulations allow for the energetic interactions between molecules to be inves‑
tigated at levels of detail inaccessible by experiment. This advantage has been high‑
lighted by two recent studies of the differences between how T‑cell receptors (TCRs)
and TCR‑mimetic antibodies (TCRms) bind their targets. TCRs are the natural immune
system’s method of identifying peptide fragments presented by human leukocyte anti‑
gens (pHLAs), in which the peptide binds the groove between the α1 and α2 helices
of the HLA. The TCR variable region recognizes pHLAs exposing non‑self peptides,
while the membrane‑bound constant region, alongside crucial co‑receptors, enables
downstream immune activation. The pharmaceutical industry is increasingly interested
in translating TCR specicity to solubilized drug formats, which require stronger target
binding. This necessitates engineering efforts to “afnity enhance” the TCR variable
domain, or the use of immune recognition domains that were not evolutionarily selected
to bind pHLAs, such as antibodies (TCRms), but which can routinely achieve binding
in the nM‑pM range.
In the work of Holland et al. (2020), all‑atom simulations were used to generate
ensembles of conformations for a set of TCRs, TCRms, and afnity‑enhanced TCRs.77
The molecular mechanic Poisson‑Boltzmann surface area (MMPBSA) method was then
used to predict the free energy difference between the bound and unbound states for
each complex, and the result decomposed into the per‑residue contributions.78 In brief,
this method uses all‑atom MD structures in concert with implicit solvent calculations
to predict free energy differences between states. Decomposition of the free energy
revealed that while afnity‑enhanced TCRs tend to have a broad binding signature char‑
acterized by strong interactions with up to three residues in the peptide antigen, TCRms
tend to have only one or two strong energetic contacts with the peptide.
Raybould et al. (2022), leveraging the increasing numbers of MX structures for
TCRms, performed a similar MD study comparing TCR, TCRm, and afnity‑enhanced
79
TCR interactions with their targets.
To provide the best comparisons possible,
Raybould and co‑workers simulated three different peptide antigens, Wilms’ Tumor 1
(WT1), New York esophageal squamous cell carcinoma 1 (NY‑ESO‑1), and p53_R175H

220 Biopharmaceutical Informatics
neoantigen (p53 R175H) bound by the same HLA in contact with various TCR, TCRm,
and afnity‑enhanced TCRs. The contributions of the peptide, α1 helix, and α2 helix to
the total free‑energy change of the pHLA were computed using the molecular mechanic
Generalized‑Born surface area approach, a technique related to MMPBSA but using a
different representation of the protein for surface area calculations. These calculations
revealed that natural and afnity‑enhanced TCRs tend to gain a larger proportion of
their binding energy from the peptide than any of the TCRms (Figure8.3d). Further,
these calculations suggested that some peptide antigens are easier to bind than others,
with WT1 peptides notably all ranking at the bottom in terms of fraction contribution
to the total free energy change in the receptor. Similar calculations carried out on the
residues in the CDRs (Figure8.3e) indicated that while the CDR[H/B]3 and CDR[L/A]3
predominate across the board, the pattern changes depending on the context. While
TCRms tend to gain more energy from CDRH3 than CDRL3, in TCRs, there is no clear
preference.
These studies into the energetics of antibody‑antigen and TCR‑antigen interactions
highlight one of the key uses of MD and molecular simulations in general: gaining
more detailed analysis than is possible experimentally. By determining which residues
contribute most strongly to binding, studies like these can serve as the beginnings of a
computational basis for mutational studies.
Case Study 8.6: Predicting aggregation‑prone
antibody therapeutics with all‑atom MD
The formation of aggregates within mAb solutions during processing and storage can
lead to the rejection of otherwise promising candidate molecules; aggregation has there‑
fore been called the “most common and troubling manifestation of protein instabil‑
ity, encountered in almost all stages of protein drug development”.80 Predicting this
behavior with small amounts of mAb material at an early stage of development is
therefore highly desirable, and computational methods have been developed to identify
and interrogate regions prone to aggregation.
81–83
Aggregation‑prone regions are spe‑
cic short‑sequence motifs that appear to be able to modulate aggregation, leading to
extensive computational investigations of their dynamics. For example, a recent study of
aggregation‑prone pentapeptides revealed that they can begin to form aggregates within
20 ns at a concentration of 0.1 M, with mutations strongly inuencing the kinetics of
aggregate assembly.83 In a recent paper, Berner and co‑workers used a combination of
two experimental unfolding reversibility methods and one simulation technique to inter‑
rogate a set of 13 candidate mAbs, including some aggregation‑prone examples.82 They
note that their work is inspired by the observation that antibodies with domains that
undergo reversible thermal unfolding also tend to be resistant to aggregation and that
antibodies that refold to monomers after unfolding with denaturant aggregate less in
formulations. In the following section, we describe the insights into aggregation they
gained from all‑atom simulations of antibody Fv regions.
82
Berner and co‑workers
performed all‑atom MD simulations of the Fv segments of
the ten antibodies for which they had access to experimental structures (Figure8.3f)
and experimental assay data. These data show the temperatures at which each of the ten
Соседние файлы в папке Библиотека им академика М.И. Перельмана
